Efficacy and Safety of the Irinotecan, Capecitabine, and Oxaliplatin (IOX) Regimen in Metastatic Gastric Cancer: A Single Arm Phase II Trial
Journal Title: Middle East Journal of Cancer - Year 2019, Vol 10, Issue 1
Abstract
Background: Gastric cancer is one of the most common malignancies worldwide with a high case mortality rate. In metastatic gastric cancer, a proper combination of chemotherapy could increase the survival rate. The goal of this study is to evaluate the efficacy and safety of the combination regimen of irinotecan, oxaliplatin, and Xeloda in metastatic gastric cancer. Methods: A total of 45 patients with metastatic gastric cancer and good performance status according to the Eastern Cooperative Oncology Group (score: 0-1) received the irinotecan, oxaliplatin, and Xeloda chemotherapy regimen. Demographic data, responses to treatment, and adverse effects were gathered for all cases. Overall survival and progression-free survival rates for patients were calculated using the Kaplan-Meier estimate. Results: Patients’ mean age was 58.3 ± 11.3 years (range: 24-81). There were 73.4% male patients and 26.6% female patients. Anorexia and weight loss were the most common symptoms. Overall response rate was 50%. The majority of toxicities were anemia, nausea and vomiting (grades 1 and 2), diarrhea (grades 1 and 2), neutropenia, alopecia, and hand and foot syndrome. The one-year progression-free survival rate was 31.5 ± 7.5%, whereas the twoyear progression-free survival rate was zero. The one-year overall survival rate was 34.91 ± 8.5%. Patients had a two-year overall survival rate of 7.7 ± 6.6%. Diffuse type cancer was linked to an inferior outcome. Conclusion: Regardless of our limited number of patients, this combination could be a suitable regimen for metastatic gastric cancer in terms of low toxicity, acceptable response rate, and survival results.
Authors and Affiliations
Saeid Anvari, Kamran Alimoghaddam, Amir Kasaeian, Mohammad Vaezi, Mohsen Rajaeinejad, Hosein Kamranzadeh Fumani, Ardeshir Ghavamzadeh
Keywords
Related Articles
- EP ID EP443470
- DOI -
- Views 85
- Downloads 0
Visfatin and its Role in Breast Cancer
Breast cancer, the most common cancer in women, is a leading cause of cancer death among women worldwide. Obesity is associated with increased risk of breast cancer. Discovery of biomarkers that can be used for diagnosis...
Relationship between MMP-11 Expression in Invasive Ductal Breast Carcinoma with its Clinicopathologic Parameters
Background: Breast cancer is one of the most common cancers in the world, particularly in Iran. There are many genomic and molecular factors that cause the occurrence of breast cancer. Many markers are associated with tu...
Struma Ovarii Associated with Pseudo-Meigs’ Syndrome: A Rare Presentation of an Infrequent Tumor
Struma ovarii is an uncommon highly specialized ovarian teratoma that accounts for less than 5% of mature teratomas. It is composed predominantly of mature thyroid tissue. Thyroid tissue is observed in 5%-15% of teratoma...
Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcin...
Pain Coping Strategies and Their Relationship with Unpleasant Emotions (Anxiety, Stress, and Depression) and Religious Coping in Cancer Patients
Background: Coping strategies affect patients’ perceptions of pain severity, their ability to tolerate pain, duration of daily activities, and emotions. This study aims to determine the relationship between pain coping a...